U.S. FDA Approves Orexo's Low Dose ZUBSOLV(R) Buprenorphine and Naloxone Sublingual Tablets (CIII)

MORRISTOWN, N.J., Oct. 6, 2016 -- (Healthcare Sales & Marketing Network) -- Orexo US announced today that the U.S. Food and Drug Administration (FDA) has approved ZUBSOLV® (buprenorphine/naloxone CIII sublingual tablet) 0.7mg/0.18mg for the treatment ... Biopharmaceuticals, FDA Orexo, ZUBSOLV, buprenorphine, naloxone

http://salesandmarketingnetwork.com/news_release_bs.html?ID=2041691

Source: HSMN NewsFeed - October 6, 2016 Category: Pharmaceuticals Source Type: news

More News: Food and Drug Administration (FDA) | Marketing | Pharmaceuticals | Suboxone